Standard Biotools (LAB) Net Income towards Common Stockholders (2016 - 2025)
Standard Biotools (LAB) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with $19.3 million as the latest value for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 156.59% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$71.9 million through Dec 2025, up 46.29% year-over-year, with the annual reading at -$74.9 million for FY2025, 59.49% up from the prior year.
- Net Income towards Common Stockholders for Q4 2025 was $19.3 million at Standard Biotools, up from -$31.7 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $19.3 million in Q4 2025, with the low at -$76.3 million in Q1 2022.
- Average Net Income towards Common Stockholders over 5 years is -$25.6 million, with a median of -$21.9 million recorded in 2024.
- The sharpest move saw Net Income towards Common Stockholders skyrocketed 165.83% in 2023, then plummeted 348.28% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$13.9 million in 2021, then plummeted by 50.34% to -$20.8 million in 2022, then surged by 165.83% to $13.7 million in 2023, then tumbled by 348.28% to -$34.1 million in 2024, then surged by 156.59% to $19.3 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at $19.3 million, -$31.7 million, and -$33.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.